Attenuation of cardiac hypertrophy in carnitine-deficient juvenile visceral steatosis (JVS) mice achieved by lowering dietary lipid.
We examined the development of cardiac hypertrophy in juvenile visceral steatosis (JVS) mice, a model of systemic carnitine deficiency, by varying the amount of lipid in the diet. Cardiac hypertrophy was markedly attenuated by decreasing soy bean oil (SBO) from 5% (w/w) to 1%. Triglyceride contents of the ventricles of JVS mice fed 1% SBO were significantly lower than in JVS mice fed 5% SBO. The addition of medium-chain triglycerides metabolically utilized by JVS mice did not affect the development of cardiac hypertrophy. On the other hand, the mRNA levels of atrial natriuretic peptide and skeletal alpha-actin, which are related to cardiac hypertrophy, were also attenuated by decreasing lipid in the diet. Adenylate energy charge and creatine phosphate in the heart of JVS mice at the early stage of hypertrophy were not significantly different from control mice given the same laboratory chow (4.6% of lipid). Although urinary prostaglandin F(2alpha) levels were found to be increased in JVS mice at 15 days of age when they developed cardiac hypertrophy, administration of aspirin was not efficacious. We, therefore, propose that the proportion of lipid in the diet is important in the development of cardiac hypertrophy in carnitine-deficient JVS mice, and that this is not related to prostaglandin formation.
Jalil
Md Abdul
MA
Department of Molecular Metabolism and Biochemical Genetics and Laboratory for Neuroanatomy, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
Horiuchi
Masahisa
M
Wakamatsu
Michiko
M
Li
Meng Xian
MX
Begum
Laila
L
Suzuki
Keiko
K
Kobayashi
Keiko
K
Oka
Tatsuzo
T
Saheki
Takeyori
T
D000818:Animals; D001241:Aspirin / Q000008:administration & dosage; D002331:Carnitine / Q000008:administration & dosage / Q000172:deficiency*; D004032:Diet; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D017379:Hypertrophy, Left Ventricular / Q000178:diet therapy* / Q000188:drug therapy / Q000473:pathology*; D008055:Lipids / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D014804:Vitamin B Deficiency
D008055:Lipids; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; D001241:Aspirin; D002331:Carnitine